Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px
Document › Details

4-Antibody AG. (8/21/06). "Press Release: 4-Antibody AG Closes CHF 6 Million Series A Financing and Appoints Sijmen de Vries as CEO". Basel.

Organisations Organisation 4-Antibody AG
  Group Agenus (Group)
  Organisation 2 BioMedInvest
  Group BioMedPartners (Group)
Product Product antibody (human)
Index term Index term 4-Antibody–SEVERAL: investment, 200608 financing round Series A CHF6m
Person Person de Vries, Sijmen (Pharming 200810– CEO before 4-Antibody CEO before Morphochem before Novartis + SKB)
     


4-Antibody, a Basel-based biotechnology company focused on exploiting its proprietary platform to develop de novo and improved fully human antibodies, today announced the closing of a CHF 6 million Series A financing and the appointment of Sijmen de Vries MD, MBA as its new CEO.

The Series A financing was provided by a consortium of existing investors including Biomedinvest AG (CH), Grazia Equity (D), Life Science Partners (NL) and Mulligan Biocapital (D). Proceeds will be used to develop internal pipeline projects initially to pre- clinical proof of concept and establish licensing partnerships with biotech and pharma partners.

Sijmen joins 4- Antibody from Morphochem AG (Munich, Germany), where he was CEO and, after successfully re-focusing the business on antibiotic development and steering its lead hospital antibiotic through pre-clinical development, he merged the company with Biovertis AG. Previous to that, he held various senior management positions at Novartis Pharma AG and SmithKline Beecham. Dr de Vries succeeds Dr Ulf Grawunder, who as co-founder of the company successfully led the company through its initial growth phases and continues to serve the company as its CSO.

“We are very pleased with the closing of this Series A financing and getting the experience that Sijmen brings on board at this exciting time for the company. Over the last year and a half the 4-Antibody technology platform matured to deliver its first exciting results on improving an existing antibody. With this financing closed we are now looking forward to the next stage of development during which we will engage in both internal and collaborative development projects for fully human antibodies” said Prof. Dr. Max Burger, Chairman of 4-Antibody AG and Chairman Novartis Science Board.

Dr. Ulf Grawunder added: “As the (co-)founding CEO, I am very pleased, to now hand over to Sijmen and to be able to fully focus on leading the research and development efforts in my new role as CSO. Both the closing of the financing and the fact that we attracted an experienced industry professional such as Sijmen means that we have now positioned the Company ideally for its next growth phase towards clinical development of our lead compounds.”

-ends


About 4-Antibody AG

4-Antibody AG is a Basel, Switzerland based privately owned company, with a wholly owned subsidiary in Jena, Germany. 4-Antibody owns a novel and proprietary technology platform for the development and/or optimization of fully human antibodies. For more information about 4-Antibody, visit our website at http://www.4-antibody.com.

Further Information:

Dr. Sijmen de Vries
CEO
4-Antibody AG
Phone +41-61-697 1353
E-Mail info@4-antibody.com

Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
Northbank Communications
t : +49 (0)89 57 00 18 06
e: d.pretsell@northbankcommunications.com

   
Record changed: 2016-03-20

Advertisement

Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 600x60px

More documents for Agenus (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wpq




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 120x240px wpctoc Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px